Imlifidase therapy: exploring its clinical uses

References

• Al-Salama ZT. Imlifidase: first Approval. Drugs. 2020;80(17):1859–1864.
   PubMed Web of Science ®Google Scholar
• Ingsathit A, Kamanamool N, Thakkinstian A, et al. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-analysis. Transplantation. 2013;95(7):943–948.
   PubMed Web of Science ®Google Scholar
• Schold JD, Buccini LD, Goldfarb DA, et al. Association between kidney transplant center performance and the survival benefit of transplantation versus dialysis. Clin J Am Soc Nephrol. 2014;9(10):1773–1780.
   PubMed Web of Science ®Google Scholar
• Cassuto J, Babu S, Laskowski I. The survival benefit of kidney transplantation in the setting of combined peripheral arterial disease and end-stage renal failure. Clin Transplant. 2016;30(5):545–555.
   PubMed Web of Science ®Google Scholar
• Haller MC, Kammer M, Oberbauer R. Dialysis vintage and outcomes in renal transplantation. Nephrol Dial Transplant. 2019;34(4):555–560.
   PubMed Web of Science ®Google Scholar
• Leffell MS. The calculated panel reactive antibody policy: an advancement improving organ allocation. Curr Opin Organ Transplant. 2011;16(4):404–409.
   PubMed Web of Science ®Google Scholar
• Roth AE, Sönmez T, Unver MU, et al. Utilizing list exchange and nondirected donation through ‘chain’ paired kidney donations. Am J Transplant. 2006;6(11):2694–2705.
   PubMed Web of Science ®Google Scholar
• Gebel HM, Kasiske BL, Gustafson SK, et al. Allocating deceased donor kidneys to candidates with high panel-reactive antibodies. Clin J Am Soc Nephrol. 2016;11(3):505–511.
   PubMed Web of Science ®Google Scholar
• Heidt S, Haasnoot GW, van der Linden-van Oevelen MJH, et al. Highly sensitized patients are well served by receiving a compatible organ offer based on acceptable mismatches. Front Immunol. 2021;12:687254
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365(4):318–326.
   PubMed Web of Science ®Google Scholar
• Kahwaji J, Jordan SC, Najjar R, et al. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transpl Int. 2016;29(12):1276–1285.
   PubMed Web of Science ®Google Scholar
• Klein K, Süsal C, Schäfer SM, et al. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Atheroscler Suppl. 2013;14(1):199–202.
   PubMed Web of Science ®Google Scholar
• Rostaing L, Maggioni S, Hecht C, et al. Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates. Exp Clin Transplant. 2015;13 Suppl 1:165–169.
   PubMed Web of Science ®Google Scholar
• Kauke T, Klimaschewski S, Schoenermarck U, et al. Outcome after Desensitization in HLA or ABO-incompatible kidney transplant recipients: a single center experience. PLoS One. 2016;11(1):e0146075.
   PubMed Web of Science ®Google Scholar
• Vo AA, Choi J, Kim I, et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (Tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. 2015;99(11):2356–2363. 0000000000000741.
   PubMed Web of Science ®Google Scholar
• Weinhard J, Noble J, Jouve T, et al. Tocilizumab and desensitization in kidney transplant candidates: personal experience and literature review. J Clin Med. 2021;10(19):4359.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Lorant T, Choi J, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017;377(5):442–453.
   PubMed Web of Science ®Google Scholar
• Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med. 2016;374(10):940–950.
   PubMed Web of Science ®Google Scholar
• Rostaing LP, Malvezzi P. HLA-Incompatible kidney transplantation–worth the risk? N Engl J Med. 2016;374(10):982–984.
   PubMed Web of Science ®Google Scholar
• Manook M, Koeser L, Ahmed Z, et al. Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis. Lancet. 2017 Feb 18;389(10070):727–734. Epub 2017 Jan 6. PMID: 28065559.
   PubMed Web of Science ®Google Scholar
• Uhlin F, Szpirt W, Kronbichler A, et al. Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: an open-label phase 2a study. J Am Soc Nephrol. 2022;33(4):829–838. Epub 2022 Mar 8. PMID: 35260419.
   PubMed Web of Science ®Google Scholar
• Wenig K, Chatwell L, von Pawel-Rammingen U, et al. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. Proc Natl Acad Sci USA. 2004;101(50):17371–17376.
   PubMed Web of Science ®Google Scholar
• Bockermann R, Järnum S, Runström A, et al. Imlifidase-generated single-cleaved IgG: implications for transplantation. Transplantation. 2021;106(7):1485–1496. Online ahead of print. PMID: 34966107.
   PubMed Web of Science ®Google Scholar
• Ge S, Chu M, Choi J, et al. Imlifidase inhibits HLA antibody-mediated NK cell activation and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Transplantation. 2020;104(8):1574–1579.
   PubMed Web of Science ®Google Scholar
• Runström A, Sjöholm K, Roupé KM, et al. IgM single antigen bead HLA-assay is affected by imlifidase through the cleavage of IgG but not IgM. Transpl Immunol. 2021;68:101436.
   PubMed Web of Science ®Google Scholar
• Winstedt L, Järnum S, Nordahl EA, et al. Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS–A Novel Therapeutic Opportunity. PLoS One. 2015;10(7):e0132011.
   PubMed Web of Science ®Google Scholar
• Lorant T, Bengtsson M, Eich T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;1811:2752–2762. Epub 2018 Apr 17. PMID: 29561066
   PubMed Web of Science ®Google Scholar
• Jordan SC, Legendre C, Desai NM, et al. Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: results of an International Phase 2 Trial (Highdes). Transplantation. 2021;105(8):1808–1817.
   PubMed Web of Science ®Google Scholar
• Kjellman C, Maldonado AQ, Sjöholm K, et al. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplant. 2021;21(12):3907–3918.
   PubMed Web of Science ®Google Scholar
• Kidney disease: improving global outcomes glomerular diseases work group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4S):S1–S276. Available at: https://kdigo.org/guidelines/gd/
   Google Scholar
• Benjamin RJ. A conceptual framework for managing iTTP. Blood. 2021;137(14):1845–1846.
   PubMed Web of Science ®Google Scholar
• Stubbs MJ, Thomas M, Vendramin C, et al. Administration of immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti-ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission. Br J Haematol. 2019;186(1):137–140.
   PubMed Web of Science ®Google Scholar